现有病毒疫苗用于防治新冠肺炎的可行性分析

doi:10.3976/j.issn.1002-4026.2020.02.001

Abstract

Abstract: The outbreak of COVID-19 is seriously endangering human and public health. It has caused great concern all around the world. The most effective measure to prevent viral diseases is vaccination. But there has no specific vaccine been approved for this disease yet. Considering the serious effect of the epidemic,this article reviewed the related vaccines research on influenza viruses and coronaviruses, and their amino acid sequences were compared. The results show that there are some similarity between the spike of 2019-nCoV and hemagglutinin from influenza A virus and influenza B virus. The hemagglutinin of influenza is the major targets of current commercial sensonal influenza vaccines which imply that vaccines might be beneficial for prevention of COVID-19. Besides that, because of the high similarity between spike and nucleocapsid of SARS-CoV and 2019-nCoV, we believe that the SARS-CoV vaccine may be an alternative that can be used for the control of COVID-19 in the short term.

Key words: COVID-19, vaccine, influenza virus, SARS-CoV, corvonavirus

CLC Number:

R183.3

SUN Chen, HE Qiu-xia, GAO Yan, ZHANG Lei, LI Ning, LIU Ke-chun. Exploring preventive measures for COVID-19 based on the existing virus vaccines[J].Shandong Science, 2020, 33(2): 1-11.

References 56

1	CHEN N S, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. The Lancet, 2020, 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7
2	中国新闻网. 黑龙江省3例新冠肺炎死亡患者均为患有慢性疾病老年人[EB/OL]. (2020-02-09)[2020-02-25].http://www.chinanews.com/sh/2020/02-09/9084552.
3	国家卫生健康委员会. 截至2月24日24时新型冠状病毒肺炎疫情最新情况[EB/OL]. (2020-02-25)[2020-02-25].http://www.nhc.gov.cn/xcs/yqtb/202002/67e6c59a84bd4f07b6ca4a4c5ffabb79.shtml.
4	国家卫生健康委办公厅. 新型冠状病毒肺炎诊断方案（试行第六版）[EB/OL]. (2020-02-19)[2020-02-25].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf.
5	北青网. 新冠肺炎康复者血浆治疗超10人临床症状明显好转[EB/OL]. (2020-02-14)[2020-02-25].https://www.xianjichina.com/news/details_185590.html.
6	PALESE P. Influenza: old and new threats[J]. Nature Medicine, 2004, 10(12): 82-87. doi: 10.1038/nm1141
7	IULIANO A D , ROGUSKI K M , CHANG H H , et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. The Lancet, 2017, 391(10127): 1285-1300. DOI:10.1016/S0140-6736(17)33293-2. doi: 10.1016/S0140-6736(17)33293-2
8	TRUCCHI C, PAGANINO C, AMICIZIA D, et al. Universal influenza virus vaccines: what needs to happen next[J]. Expert Opinion on Biological Therapy, 2019, 19(7): 671-683. doi: 10.1080/14712598.2019.1604671
9	高福, 施一. 中国流感病毒结构生物学研究:40年回眸[J]. 生物化学与生物物理进展, 2014(10): 1029-1033.
10	DU L Y, ZHOU Y S, JIANG S B. Research and development of universal influenza vaccines[J]. Microbes and Infection, 2010, 12(4): 280-286. doi: 10.1016/j.micinf.2010.01.001
11	FOUCHIER R A M, MUNSTER V, WALLENSTEN A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls[J]. Journal of Virology, 2005, 79(5): 814-2822. doi: 10.1128/jvi.79.5.2814-2822.2005
12	SKEHEL J J, WILEY D C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin[J]. Annual Review of Biochemistry, 2000, 69(1): 531-569. doi: 10.1146/annurev.biochem.69.1.531
13	FONI E, CHIAPPONI C, BAIONI L, et al. Influenza D in Italy: towards a better understanding of an emerging viral infection in swine[J]. Scientific Reports, 2017, 7(1): 11660. doi: 10.1038/s41598-017-12012-3
14	中国疾病预防控制中心. 中国流感疫苗预防接种技术指南（2019—2020）[EB/OL].(2019-10-16)[2020-02-25].http://www.chinacdc.cn/jkzt/crb/bl/lxxgm/jszl_2251/201910/t20191016_206297.html.
15	HANNOUN C. The evolving history of influenza viruses and influenza vaccines[J]. Expert Review of Vaccines, 2013, 12(9): 1085-1094. doi: 10.1586/14760584.2013.824709
16	BERLANDA SCORZA F, TSVETNITSKY V, DONNELLY J J. Universal influenza vaccines: shifting to better vaccines[J]. Vaccine, 2016, 34(26): 2926-2933. doi: 10.1016/j.vaccine.2016.03.085
17	AMBROSE C S, LEVIN M J. The rationale for quadrivalent influenza vaccines[J]. Human Vaccines & Immunotherapeutics, 2012, 8(1): 81-88. doi: 10.4161/hv.8.1.17623
18	JAZAYERI S D, POH C L. Development of universal influenza vaccines targeting conserved viral proteins[J]. Vaccines, 2019, 7(4): 169. doi: 10.3390/vaccines7040169
19	KUBO H, YAMADA Y K, TAGUCHI F. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein[J]. Journal of Virology, 1994, 68(9): 5403-5410. doi: 10.1128/jvi.68.9.5403-5410.1994
20	MCBRIDE R, VAN ZYL M, FIELDING B. The coronavirus nucleocapsid is a multifunctional protein[J]. Viruses, 2014, 6(8): 2991-3018. doi: 10.3390/v6082991
21	HAMRE D, PROCKNOW J J. A new virus isolated from the human respiratory tract[J]. Experimental Biology and Medicine, 1966, 121(1): 190-193. doi: 10.3181/00379727-121-30734
22	HENDLEY J O, FISHBURNE H B,Jr GWALTNEY J M. Coronavirus infections in working adults eight-year study with 229 E and OC 43[J]. The American Review of Respiratory Disease, 1972, 105(5): 805-811. doi: 10.1164/arrd.1972.105.5.805
23	der VAN H L, PYRC K, JEBBINK M F, et al. Identification of a new human coronavirus[J]. Nature Medicine, 2004, 10(4): 368-373. doi: 10.1038/nm1024
24	FRIEDMAN N, ALTER H, HINDIYEH M, et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU[J]. Viruses, 2018, 10(10): 515. doi: 10.3390/v10100515
25	孟娟丽, 沈晓玲, 谭文杰. SARS冠状病毒病毒样颗粒疫苗的研究进展[J]. 生物技术通讯, 2014,25(2): 268-271. doi: 10.3969/j.issn.1009-0002.2014.02.027
26	B-EZ-SANTOS Y M, ST J S E, MESECAR A D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds[J]. Antiviral Research, 2015, 115: 21-38. doi: 10.1016/j.antiviral.2014.12.015
27	LUIS E, MARTA LDD, ENRIQUE A, et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease[J]. Virus Research, 2008, 133(1): 45-62. doi: 10.1016/j.virusres.2007.01.021
28	广东省防治非典型肺炎科技攻关疫苗专题组.SARS 冠状病毒灭活疫苗研究初报[J].广东医学,2003,24(增刊1):129-130. DOI：10.13820/j.cnki.gdyx.2003.s1.051. doi: 10.13820/j.cnki.gdyx.2003.s1.051
29	曾玉红. SARS 疫苗研究进展[J]. 国际免疫学杂志,2007, 30( 4) : 266-269. doi: 10.3760/cma.j.issn.1673-4394.2007.04.018
30	MARSHALL E, ENSERINK M. Medicine. Cautionurged on SARS vaccines[J]. Science, 2004, 303(5660): 944-946. doi: 10.1126/science.303.5660.944
31	RACHEL L G, ERIC F D, RALPH S B. A decade after SARS: strategies for controlling emerging coronaviruses[J]. Nature Reviews Microbiology, 2013, 11(12): 836-848. doi: 10.1038/nrmicro3143
32	LI F, LI W, FARZAN M et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 2005, 309(5742): 1864-1868. doi: 10.1126/science.1116480
33	GUPTA V, TABIIN T M, SUN K, et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens[J]. Virology, 2006, 347(1): 127-139. doi: 10.1016/j.virol.2005.11.042
34	FETT C, DEDIEGO M L, REGLANAVA J A, et al. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein[J]. Journal of Virology, 2013, 87(12): 6551-6559. doi: 10.1128/JVI.00087-13
35	GRAHAM R L, BECKER M M, ECKERLE L D, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease[J]. Nature Medicine, 2012, 18(12): 1820-1826. doi: 10.1038/nm.2972
36	BISHT H, ROBERTS A, VOGEL L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice[J]. Proceedings of the National Academy of Sciences, 2004, 101(17): 6641-6646. doi: 10.1073/pnas.0401939101
37	BUCHHOLZ U J, BUKREYEV A, YANG L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(26): 9804-9809. doi: 10.1073/pnas.0403492101
38	FABER M, LAMIRANDE E W, ROBERTS A, et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies[J]. Journal of General Virology, 2005, 86(5): 1435-1440. doi: 10.1099/vir.0.80844-0
39	KAPADIA S U, ROSE J K, LAMIRANDE E, et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine[J]. Virology, 2005, 340(2): 174-182. doi: 10.1016/j.virol.2005.06.016
40	LIU S J, LENG C H, LIEN S P, et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates[J]. Vaccine, 2006, 24(16): 3100-3108. doi: 10.1016/j.vaccine.2006.01.058
41	CHEN Z, ZHANG L, QIN C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region[J]. Journal of Virology, 2005, 79(5): 2678-2688. doi: 10.1128/JVI.79.5.2678-2688.2005
42	WOO P C Y, LAU S K P, TSOIH W , et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus[J]. Vaccine, 2005, 23(42): 4959-4968. doi: 10.1016/j.vaccine.2005.05.023
43	SHI S Q, PENG J P, LI Y C, et al. The of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization[J]. Molecular Immunology, 2006, 43(11): 1791-1798. doi: 10.1016/j.molimm.2005.11.005
44	HUI D S, AZHAR E I, KIM Y J, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission[J]. The Lancet Infectious Diseases, 2018, 18(8): e217-e227. doi: 10.1016/S1473-3099(18)30127-0
45	World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)[EB/OL].[2020-02-25].https://www.who.int/emergencies/mers-cov/en/.
46	CHAFEKAR A, FIELDING B C. MERS-CoV: understanding the latest human coronavirus threat[J]. Viruses, 2018, 10(2): E93. DOI:10.3390/v10020093. doi: 10.3390/v10020093
47	ZHOU Y S,JIANG S B,DU L Y.Prospects for a MERS-CoV spike vaccine[J].Expert Review of Vaccines, 2018, 17(8): 677-686. doi: 10.1080/14760584.2018.1506702
48	LEE J Y, BAE S, MYOUNG J. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design[J]. Journal of Microbiology, 2019, 57(9): 803-811. doi: 10.1007/s12275-019-9272-7
49	CHAN J W, KOK K H, ZHU Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerging Microbes Infections, 2020, 9(1): 221-236. doi: 10.1080/22221751.2020.1719902
50	CERAOLO C, GIORGI F M. Genomic variance of the 2019-nCoV coronavirus[EB/OL]. (2020-02-06)[2020-02-25].https://doi.org/10.1002/jmv.25700. doi: doi.org/10.1002/jmv.25700
51	BENVENUTO D, GIOVANNETTI M, CICCOZZI A, et al. The 2019-new coronavirus epidemic: Evidence for virus evolution[EB/OL].(2020-01-29)[2020-02-25].https://doi.org/10.1002/jmv.25688. doi: 10.1002/jmv.25688
52	WRAPP D, WANG N, CORBETT K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[EB/OL]. (2020-02-15)[2020-02-25]. https://doi.org/ 10.1126/science.abb2507. doi: 10.1126/science.abb2507
53	陈晶, 金焱, 马可欣. 非典时期我们没有用上疫苗,这次能吗？[EB/OL]. (2020-02-11)[2020-02-25]. https://xw.qq.com/cmsid/20200210A0PSHN00.
54	医诺医学. 好消息！Vir 鉴定出两种可与新冠肺炎病毒结合的单克隆抗体[EB/OL]. (2020-02-13)[2020-02-25]. http://www.ulabmed.com/content-154-5248-1.html.
55	医麦客. 新冠疫苗：Moderna完成临床级产品的生产分装，即将投入临床 [EB/OL]. (2020-02-12)[2020-02-25]. https://xueqiu.com/5603603160/141073949.
56	周烨真, 张世豪, 陈嘉仪, 等.新型冠状病毒SARS-CoV-2的变异和进化分析J . 南方医科大学学报，2020，40(2): 152-158. doi: 10.12122/j.issn.1673-4254.2020.02.02

[1]	ZHU Jie, WANG Zheng, LIANG Yanni. The mechanism of Xiaoqinglong Decoction in treatment of COVID-19 based on network pharmacology [J]. Shandong Science, 2023, 36(3): 10-17.
[2]	DU Hai-tao, WANG Ping, LI Na, DING Jie, ZHANG Jing, YUAN Cheng-min, SUN Tie-feng, HAN Li, ZHANG Zhong-fa. Study on the medication mechanism of COVID-19 Sanjiao-Cold-Dampness Syndrome based on network pharmacology and molecular docking [J]. Shandong Science, 2021, 34(1): 1-9.
[3]	LIU Jing-hua, TAN Wang-xiao, WANG Si-wei, WANG Yu, WANG Xiao-ying. Study on the mechanism of Tingli Dazao Xiefei decoction in the treatment of COVID-19 based on the network pharmacology [J]. Shandong Science, 2020, 33(5): 1-13.
[4]	WANG Zong-qing, NIE Hong-ke, LI Qing-xuan, WANG Xing-qiang, TANG Xiao-hu. Mechanism of Huangqi Liujunzi decoction in treating the recovery stage of COVID-19 based on network pharmacology [J]. Shandong Science, 2020, 33(5): 14-26.
[5]	SUN Hui-nan, GAO Guang-heng , LIU Qing-ai , MA Yao-hong, LI Jing , SHI Jian-guo. Application of blood lactic acid biosensor in the diagnosis and treatment of COVID-19 [J]. Shandong Science, 2020, 33(3): 1-6.
[6]	SUN Qiang, BIAN Xin . Analysis and response of COVID-19 prevention planning based on ultraviolet and wind environment simulation in Wuhan Leishenshan Hospital [J]. Shandong Science, 2020, 33(3): 7-17.
[7]	XU Rui-dong, TIAN Ming-wei. Advances in research on disposable medical protective clothing [J]. Shandong Science, 2020, 33(3): 18-27.
[8]	WANG Feng-xia, ZHANG Yun, LIU Ke-chun. Prevention and control strategies of COVID-19 based on theory of principle, method and prescription of Treatise on Febrile Diseases [J]. Shandong Science, 2020, 33(2): 12-16.
[9]	NIU Ling, JING Yuan-wang, LUO Lin. Application of intelligent transportation during joint prevention and control of the epidemic [J]. Shandong Science, 2020, 33(2): 17-21.

Exploring preventive measures for COVID-19 based on the existing virus vaccines

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 56

Related Articles 9

Metrics

Comments

Recommended 0